Lighten up, John. After all, we're all gonna make money here. I don't see the real need for the PR because they could have just waited for the outcome of the bidding process. I think they just wanted to brag a little, or a lot, that there are many parties interested in the Isonep rights, and that the pps should not be tanking, but rising. It was a good move on their part to keep holders excited. Disappointing though that pps didn't go up and stay much higher.
It's the fed "tapir" again, outrunning the bulls. Biotechs driven up momentarily to be driven down again. Down 10% the last 2 weeks.
I've been adding at this low 4's. I still have the sub-4s that I bought during the last drop, sold the ones I bought at 5s in the recent pop, now buying again little by little. Will buy much more if manipulators use the Pfizer agreement angle to pull this down again. Meanwhile, ASH is bringing some excitement to the blood onco stocks. Now, what will our legislators do to the stock market come January?
This is a buy and hold since they are still into ph2, not approval like VNDA. But encouraging ASH update will drive this up, followed by ph2 conclusions in ASCO 2014. A partner would be nice after that. Of course, you could play it as buy, sell, buy, sell, too, with those anticipated events.
I was long VNDA but sold too early after their schizo drug approval, bec I thought an alarm clock will work as well for the blind.
Anyway, best of luck.
And I tried to add in the 40 something after reading the ASH abstracts and asked too low! So many appetizers and main courses being offered at ASH!
Have you looked at ADXS? They have a HER2 directed bacterial vaccine for dogs (and HPV vaccines for ovarian cancers in humans, the lesser animal). Amazing how many billions are spent on pets just in the US alone.
And manipulated back down because so they can load up before the anticipated pop pop on Monday, hopefully back up to 6 or 8. Mgmt seems to really know what they are doing with the combo trials.
I just think pps was manipulated up too high, too fast, considering the high risk, early clinical stage, and copycat status.
Well, TGR1202 is in the same class as idelalisib, while TG1101 is in the same class as rituximab. Hopefully, both these drugs will perform as well, of not better than those two first-in-class drugs. TG is not much into developing new classes of drugs, but if they can at least duplicate the success of idelalisib and rituximab, there will be a market waiting for their drugs. If any one them does better than their class-mate, then we're bound to make more money with your investment. At least we know that there is strong basis for their science.
On idelalisib (PI3K inhibitor) and rituximab. Median PFS of pts treated with IDELA + R was not reached and for placebo + R was 5.5 mos. At 24 wks, the PFS rate for IDELA +R was 93% compared to 46% for placebo + R.
2015 is completion, but update for DLBCL will be presented on Dec 9 in the ASH meeting.
are preparing to use the anticipated announcement of the termination of Pfizer and Isonep deal to walk pps down and eventually drive pps off the cliff again. Buying opportunity once again for longs. Prepare your barrels of dry gunpowder. I made some change during Act I. I hope to make some more in Act II of this never ending Wall Street manipulation drama. Or is it comedy?
Happy gobble-gobble everyone.